Somatropin treatment of spinal muscular atrophy: A placebo-controlled, double-blind crossover pilot study

详细信息    查看全文

• 作者：J. Kirschner ; D. Schorling ; D. Hauschke ; C. Rensing-Zimmermann ; U. Wein ; U. Grieben ; G. Schottmann ; U. Schara ; K. Konrad ; W. M眉ller-Felber ; S. Thiele ; E. Wilichowski ; E. Hobbiebrunken ; G.M. Stettner ; R. Korinthenberg
• 关键词：Spinal muscular atrophy ; Growth hormone ; Randomized placebo-controlled trial ; Hand-held myometry
• 刊名：Neuromuscular Disorders
• 出版年：February, 2014
• 年：2014
• 卷：24
• 期：2
• 页码：134-142
• 全文大小：975 K

文摘

In preclinical studies growth hormone and its primary mediator IGF-1 have shown potential to increase muscle mass and strength. A single patient with spinal muscular atrophy reported benefit after compassionate use of growth hormone. Therefore we evaluated the efficacy and safety of growth hormone treatment for spinal muscular atrophy in a multicenter, randomised, double-blind, placebo-controlled, crossover pilot trial. Patients (n = 19) with type II/III spinal muscular atrophy were randomised to receive either somatropin (0.03 mg/kg/day) or placebo subcutaneously for 3 months, followed by a 2-month wash-out phase before 3 months of treatment with the contrary remedy. Changes in upper limb muscle strength (megascore for elbow flexion and hand-grip in Newton) were assessed by hand-held myometry as the primary measure of outcome. Secondary outcome measures included lower limb muscle strength, motor function using the Hammersmith Functional Motor Scale and other functional tests for motor function and pulmonary function. Somatropin treatment did not significantly affect upper limb muscle strength (point estimate mean: 0.08 N, 95% confidence interval (CI:鈭?.79;3.95, p = 0.965), lower limb muscle strength (point estimate mean: 2.23 N, CI:鈭?.19;6.63, p = 0.302) or muscle and pulmonary function. Side effects occurring during somatropin treatment corresponded with well-known side effects of growth hormone substitution in patients with growth hormone deficiency. In this pilot study, growth hormone treatment did not improve muscle strength or function in patients with spinal muscular atrophy type II/III.